Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_assertion type Assertion NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_head.
- NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_assertion description "[Mutation analysis was performed in 131 of 132 (99.3%) NSCLC patients (70F/62M) with confirmed lymph node metastases (94/132 (71.2%) adenocarcinoma; 17/132 (12.8%) squamous cell; 2/132 (0.15%) large cell neuroendocrine; 1/132 (0.07%) large cell carcinoma; 18/132 (13.6%) NSCL-not otherwise specified (NOS)).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_provenance.
- NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_assertion evidence source_evidence_literature NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_provenance.
- NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_assertion SIO_000772 21949883 NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_provenance.
- NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_assertion wasDerivedFrom befree-20150227 NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_provenance.
- NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_assertion wasGeneratedBy ECO_0000203 NP591584.RARnN_BCPTjbtd_PR_pnb9M0VligkyAMFsbBHwXBVt58A130_provenance.